Mechanistic analysis elucidating the relationship between Lys96 mutation in Mycobacterium tuberculosis pyrazinamidase enzyme and pyrazinamide susceptibility

摘要

Pyrazinamide (PZA) is one of the most effective first line treatments against tuberculosis disease. The drug generally has bacteriostatic action. It also acts on bacterial spores which eliminates the chances of resurfacing of the infection. However, in recent years there has been a major increase in the occurrence of drug resistant bacterial strains. Resistance against PZA is caused by mutations in pyrazinamidase (PncA) protein which is the activator of the prodrug PZA. In the present study, we havetried to gain insights into the mechanism by which resistance develops due to K96R mutation occurring in the PncA catalytic region